CISATRACURIUM BESYLATE INJECTION USP MULTIDOSE DIN 02408813
Status: Marketed
Holder: OMEGA LABORATORIES LIMITED
Molecule: CISATRACURIUM (CISATRACURIUM BESYLATE)
Available to quote
Health Canada record
| Active ingredient(s) | CISATRACURIUM (CISATRACURIUM BESYLATE) 2 MG |
|---|---|
| Dosage form | Solution |
| Route | Intravenous |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | M03AC11 CISATRACURIUM |
| Original market date | 20-Jan-2014 |
| Current status date | 27-Sep-2024 |
| Source | Health Canada DPD |
Establishment licence of the holder
Omega Laboratories Ltd. (now Juno Pharma Canada Inc.) — licence 100277, not currently licensed, last inspection rating C (2025-05-20).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing CISATRACURIUM (CISATRACURIUM BESYLATE)
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02423782 | CISATRACURIUM BESYLATE INJECTION MULTI-DOSE | FRESENIUS KABI CANADA LTD | Solution | CISATRACURIUM (CISATRACURIUM BESYLATE) 2 MG | Approved |
| 02423774 | CISATRACURIUM BESYLATE INJECTION SINGLE DOSE | FRESENIUS KABI CANADA LTD | Solution | CISATRACURIUM (CISATRACURIUM BESYLATE) 2 MG | Approved |
| 02563266 | CISATRACURIUM BESYLATE INJECTION USP MULTI-DOSE | STERIMAX INC | Solution | CISATRACURIUM (CISATRACURIUM BESYLATE) 2 MG | Marketed |
| 02557665 | CISATRACURIUM BESYLATE INJECTION, USP MULTI-DOSE | HIKMA CANADA LIMITED | Solution | CISATRACURIUM (CISATRACURIUM BESYLATE) 2 MG | Approved |
| 02408856 | AJ-CISATRACURIUM | AGILA JAMP CANADA INC | Solution | CISATRACURIUM (CISATRACURIUM BESYLATE) 2 MG | Cancelled Pre Market |
| 02408848 | AJ-CISATRACURIUM | AGILA JAMP CANADA INC | Solution | CISATRACURIUM (CISATRACURIUM BESYLATE) 2 MG | Cancelled Pre Market |
| 02425718 | CISATRACURIUM BESYLATE INJECTION | PFIZER CANADA ULC | Solution | CISATRACURIUM (CISATRACURIUM BESYLATE) 2 MG | Cancelled Post Market |
| 02457385 | CISATRACURIUM BESYLATE INJECTION | ACCORD HEALTHCARE INC | Solution | CISATRACURIUM (CISATRACURIUM BESYLATE) 2 MG | Cancelled Pre Market |
| 02406519 | CISATRACURIUM BESYLATE INJECTION | MYLAN PHARMACEUTICALS ULC | Solution | CISATRACURIUM (CISATRACURIUM BESYLATE) 2 MG | Cancelled Pre Market |
| 02406527 | CISATRACURIUM BESYLATE INJECTION (PRESERVATIVE-FREE) | MYLAN PHARMACEUTICALS ULC | Solution | CISATRACURIUM (CISATRACURIUM BESYLATE) 2 MG | Cancelled Pre Market |
| 02408805 | CISATRACURIUM OMEGA SINGLE DOSE | OMEGA LABORATORIES LIMITED | Solution | CISATRACURIUM (CISATRACURIUM BESYLATE) 2 MG | Dormant |
| 02229422 | NIMBEX | ABBVIE CORPORATION | Liquid | CISATRACURIUM (CISATRACURIUM BESYLATE) 2 MG | Cancelled Post Market |
| 02229423 | NIMBEX 10MG/ML | ABBOTT LABORATORIES, LIMITED | Liquid | CISATRACURIUM (CISATRACURIUM BESYLATE) 10 MG | Cancelled Post Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 34103 | 2024-09-27 | Supplement to an Abbreviated New Drug Submission (SANDS) | Administrative: Change in product name |
| 14510 | 2013-06-28 | Abbreviated New Drug Submission (ANDS) |